• Biomolecules & Therapeutics
• /
• 제15권3호
• /
• pp.133-136
• /
• 2007

Human papillomavirus (HPV) infection is the most common sexually transmitted disease in the United States. An estimated 6.2 million people are infected with HPV every year. Randomized controlled studies consistently show that HPV vaccine is effective in preventing infection and HPV related cervical lesions. In June 2006, Gardasil (qadrivalent HPV recombinant vaccine) was approved by the FDA for use in females 9-26 years of age. This article reviews published data to evaluate the effectiveness of HPV vaccine for the prevention of cervical cancer.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권3호
• /
• pp.1363-1368
• /
• 2016

Human papillomavirus (HPV) is a prevalent sexually transmitted infection with serious medical, sexual, and relationship consequences. HPV vaccine protection is available globally but unfortunately vaccine uptake is inconsistent everywhere. From this study, it was observed that the awareness of cervical cancer, HPV virus and HPV vaccination in Malaysia is high, at 83.1%, 73.9% and 73.3% of respondents, respectively. However, a considerably low percentage had undergone HPV vaccination (8.6%) compared to those who had experienced a Pap smear (32.9%). Awareness between cervical cancer and HPV virus and vaccination was low. Health care providers and the governing bodies have to play a vital role in disseminating holistic information on the vaccine and the importance of getting vaccinated to the public more vigorously in Malaysia.

• 기본간호학회지
• /
• 제21권4호
• /
• pp.457-465
• /
• 2014

Purpose: The purpose of this study was to apply Ajzen's theory of planned behavior to identify factors that affect undergraduate women's decisions to receive human papillomavirus(HPV) vaccination. Method: The research design for this study was a descriptive survey design using convenience sampling. Data collection was done using self-report questionnaires with 254 undergraduate students in G city. Data were analyzed using percentage, mean, standard deviation, t-test, ANOVA, Mann-Whitney U test, Pearson correlation analysis and multiple regression with the SPSS Win 20.0 Program. Results: The mean score of intention to receive HPV vaccine was $3.88{\pm}1.05$ out of a possible 7. Intention to receive HPV vaccine showed a significantly positive correlation with attitudes (r=.26, p<.001), subjective norm (r=.51, p<.001), perceived behavior control (r=.41, p<.001) to receive HPV vaccination. In the multiple regression analysis, subjective norm and perceived behavior control to receive HPV vaccine were significant predictors and explained 33.7% of intention to receive HPV vaccine. Conclusion: Results of this study show that there are significant factors affecting the intention of undergraduate women to receive HPV vaccination. Also, strategies emphasizing subjective norm and perceived behavior control in obtaining HPV vaccination should be taken into account in developing educational programs.

• 여성건강간호학회지
• /
• 제17권4호
• /
• pp.415-425
• /
• 2011

Purpose: This study was done to identify and compare factors associated with intention to receive Human Papillomavirus (HPV) vaccine between male and female undergraduate students. Methods: In the fall of 2010, 479 students responded to self-administered questionnaires about their intention to receive HPV vaccine, HPV knowledges, HPV related involvements and optimistic bias, subject's characteristics including opinion about HPV vaccine. Mann-Whitney U test, uni-variate and multi-variate logistic regression were used for data analysis with SPSS/WIN. Results: Intention to receive vaccine were 22.0% of men and 25.0% of women. There were significantly different in HPV knowledge (Z=-2.74, p=.006), optimistic bias (Z=-4.60, p<.001), vaccine is necessary for women (Z=-4,30, p<.001), vaccine is necessary for men (Z=-4.37, p<.001), vaccine is necessary if only symptom exist (Z=-4.52, p<.001), but there were not different in intention to receive vaccine, involvement between men and women. Concern about vaccine safety (OR=3.19, 95% CI 1.63~6.23) was determinant of intention to receive HPV vaccine for men. Conclusion: This study showed gender differences in HPV knowledge, HPV related optimistic bias and opinion about HPV vaccine, which would be assessed and well managed in tailored HPV education for enhancing HPV vaccine acceptance.

• Journal of Microbiology and Biotechnology
• /
• 제25권6호
• /
• pp.936-940
• /
• 2015

Human papillomavirus (HPV) type 52 is a high-risk HPV responsible for cervical cancer. HPV type 52 is common around the world and is the most common in some Asian regions. The available prophylactic HPV vaccines protect only from HPV types 16 and 18. Supplementing economical vaccines that target HPV type 52 may satisfactorily complement available prophylactic vaccines. A codon-adapted HPV 52 L1 gene was expressed in the methylotrophic yeast Hansenula polymorpha, which is used as an industrial platform for economical hepatitis B surface antigen particle production in China. We found that the recombinant proteins produced in this expression system could form virus-like particles (VLPs) with diameters of approximately 50 nm. This study suggests that the HPV 52 VLPs produced in this platform may satisfactorily complement available prophylactic vaccines in fighting against HPVs prevalent in Asia.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권6호
• /
• pp.2447-2451
• /
• 2014

Human papillomavirus (HPV) is the primary etiologic agent of cervical cancer. Consideration of safety and non human leukocyte antigen restriction, protein vaccine has become the most likely form of HPV therapeutic vaccine, although none have so far been reported as effective. Since tumor cells consistently express the two proteins E6 and E7, most therapeutic vaccines target one or both of them. In this study, we fabricated DC vaccines by transducing replication-defective recombinant adenoviruses expressing E6/E7 fusion gene of HPV-16, to investigate the lethal effects of specific cytotoxic T lymphocytes (CTL) against CaSki cells in vitro. Mouse immature dendritic cells (DC) were generated from bone marrow, and transfected with pAd-E6/E7 to prepare a DC vaccine and to induce specific CTL. The surface expression of CD40, CD68, MHC II and CD11c was assessed by flow cytometry (FCM), and the lethal effects of CTL against CaSki cells were determined by DAPI, FCM and CCK-8 methods. Immature mouse DC was successfully transfected by pAd-E6/E7 in vitro, and the transfecting efficiency was 40%-50%. A DC vaccine was successfully prepared and was used to induce specific CTL. Experimental results showed that the percentage of apoptosis and killing rate of CaSki cells were significantly increased by coculturing with the specific CTL (p <0.05). These results illustrated that a DC vaccine modified by HPV-16 E6/E7 gene can induce apoptosis of CaSki cells by inducing CTL, which may be used as a new strategy for biological treatment of cervical cancer.

• 종양간호연구
• /
• 제11권3호
• /
• pp.193-199
• /
• 2011

Purpose: This study was aimed to examine mothers'knowledge about human papillomavirus (HPV)vaccination to prevent cervical cancer in Korea. Methods: From September 20 to October 10 2011, 101 mothers who have adolescent girls were surveyed with questionnaires about their general characteristics, the knowledge of HPV vaccine, inoculation rate and vaccination-related factors of their daughters. Results: The percentage of correct answers for HPV vaccine knowledge was 24.2% and the HPV vaccination rate was only 5.9%. HPV vaccine knowledge score of the vaccination group was significantly higher than that of the non-vaccinated group. Mothers said that the reasons why they didn't vaccinate their daughters against the HPV was the financial burden, the lack of HPV knowledge, and worries about possible side effects. The participants addressed that they understood the appropriate age for vaccination was sixteen. Conclusion: We recommend that more educational and promotional efforts need to be given for mothers in order to improve their knowledge of HPV vaccination and to increase the performance rates of HPV immunization against cervical cancer for their daughters.

• Journal of Korean Medical Science
• /
• 제33권52호
• /
• pp.331.1-331.17
• /
• 2018

Human Papillomavirus (HPV) infection is the most common sexually transmitted infection and is associated with the development of cervical cancer. The purpose of this report is to provide the literature evidences on selecting the HPV vaccine for national immunization program (NIP) in Korea. To complete these tasks, we reviewed domestic and foreign literature on the current status of HPV infection, efficacy and effectiveness of HPV vaccine, safety of vaccine and cost effectiveness analysis of vaccination business. Given that the median age of first sexual intercourse is continuing to fall, this may have serious implications for HPV infection and cervical cancer incidence at the age of 20s. The World Health Organization recommends that the HPV vaccination should be included in the NIP being implemented in each country. Both the bivalent and quadrivalent vaccines have a 90% or greater preventive efficacy on cervical intraepithelial lesion 2-3 and cervical cancer by the HPV 16 or HPV 18. In the future, if HPV vaccination rate as part of NIP increases, it is expected that the incidence of HPV infection, genital warts, and cervical precancerous lesions will be decreased in the vaccination age group. Therefore, in order to increase the HPV vaccination rate at this point in Korea, social consensus and efforts such as the introduction and promotion of HPV vaccine to the NIP according to appropriate cost-effectiveness analysis are required.

• Journal of Microbiology
• /
• 제40권4호
• /
• pp.313-318
• /
• 2002

To perform the prophylactic study of a vaccine derived from human papillomavirus (HPV) using Balb/c mice, we produced virus like particles consisting of HPV capsid protein L1 which has been reported to induce significant humoral and cellular immunity using various animal model systems. In order to produce HPV16 VLPs, the cDNA of L1 capsid protein in HPV type 16, obtained by polymerase chain reaction, was inserted into yeast expression vector, YEG$\alpha$-HIR525 under the control of GAL10 promoter. The transformation of YEG$\alpha$-HPV16 L1 was performed into the yeast Saccharomyces cerevisiae Y2805 by the lithium acetate method and the yeast clone expressing the highest level of L1 capsid protein of human papillomavirus type 16 was selected by Western blot analysis using anti-HPV16 L1 antibody. The purification of HPV16 VLP has been performed by the ultracentrifugation and gel-filtration methods. To validate the vaccine efficacy of the purified HPV16 VLPs and investigate the properties of HPV16 VLPs to induce humoral immunity, ELISA assay was performed. A significantly increased production of anti-HPV16 VLP antibodies was observed in sera from immunized mice. The neutralization activity of antibodies in the sera from the vaccinated mice was demonstrated by a rapid and simple assay to detect hemagglutihation inhibition activity.

• 항공우주의학회지
• /
• 제31권1호
• /
• pp.21-23
• /
• 2021

Purpose: Human papillomavirus (HPV) vaccination schedule is recommended by Strategic Advisory Group of Experts on Immunization of World Health Organization to achieve high efficacy and immunogenicity. However, the patients often cannot keep up their schedule for several reasons. Methods: Monthly numbers of visitors for HPV vaccination between 2019 and 2021 were analyzed to measure the impact of coronavirus disease-19 (COVID-19) outbreak which was the main cause of this delay. Results: In February 2020, the number of foreign patients vaccinated with HPV was dropped suddenly due to COVID-19. Prior to this impact, the average patients per month for HPV vaccination was 160 (95% confidence interval [CI]: 143-176). It was then 30 (95% CI: 20-40). However recent trends show a gradual recovery. Conclusion: If a woman is pregnant after starting the HPV vaccine series, the reminder doses should be delayed until she is no longer pregnant. If this series is interrupted for any length of time, it can be resumed without restarting the series. HPV vaccine series need to be administered with a minimum interval of 14 days before or after administration of COVID-19 vaccines.